METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX)

Sponsor
Centre Hospitalier Universitaire de Nice (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05821517
Collaborator
(none)
150
1
3
21.1
7.1

Study Details

Study Description

Brief Summary

Anterior shoulder dislocation is a pathology frequently encountered in emergency medicine.

The success in reducing anterior shoulder dislocations depends on muscle relaxation, which is itself conditioned by the patient's pain and apprehension. However, there is no consensus on the optimal technique for reducing anterior shoulder dislocation or the analgesia associated with it.

Analgesia with METHOXYFLURANE showed a greater reduction in post-traumatic pain compared to standard analgesic treatment and faster action of METHOXYFLURANE. A retrospective study which has compared analgesia with METHOXYFLURANE and analgesic sedation with PROPOFOL found a shoulder reduction success rate of 80% and a reduction in the average length of stay in the emergency department.

Finally, the use of virtual reality in pain management is emerging in our practices by allowing pre- and per-procedure hypno-sedation-analgesia. However, the use of virtual reality headsets has not been studied in the management of anterior shoulder dislocation.

The use of these two techniques could therefore limit the use of procedural sedation in the context of shoulder dislocation reduction.

Condition or Disease Intervention/Treatment Phase
  • Device: Helmet virtual reality.
  • Drug: Administration of METHOXYFLURANE
  • Drug: Standard of care
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard of care

An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.

Drug: Standard of care
An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating scale is administred prior to the reduction procedure. Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.

Experimental: Medical device : VR headset

Use of a " virtual reality " (VR) headset of " Pico G2 " type with " HypnoVR " software and audio headset " Taotronics BH22 " during all the reduction care

Device: Helmet virtual reality.
Use of a " virtual reality " (VR) headset of " Pico G2 " type with " HypnoVR " software and audio headset " Taotronics BH22 " during all the reduction care

Experimental: Medication : Methoxyflurane analgesia

Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)

Drug: Administration of METHOXYFLURANE
Self administered inhalated methoxyflurane (maximal inhaled dose : 3 mL)

Outcome Measures

Primary Outcome Measures

  1. Decrease in the rate of procedural sedation of anterior shoulder dislocation [Day 1 (day of reduction of anterior shoulder dislocation)]

    Rate of use of procedural sedation for anterior shoulder dislocation reduction in the interventional groups compared to the control group

Secondary Outcome Measures

  1. The amount of co-antalgesics administered [3 months]

    Posology of co-analgesic medications administered

  2. The duration of the procedure [Day 1 (day of reduction of anterior shoulder dislocation)]

    Time lenght of the reduction procedure

  3. The dosage of drugs used in procedural sedation [Day 1 (day of reduction of anterior shoulder dislocation)]

    Posology of sedative drugs administered for a procedural sedation

  4. The average length of stay in the emergency department [3 months]

    Average length of stay in the emergency department

  5. Patient satisfaction [3 months]

    Patient satisfaction at the end of care evaluated with a questionnaire

  6. The rate of reduction-related complications [3 months]

    Complications related to the reduction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pregnant and/or breastfeeding women and women of childbearing age who do not have effective contraception (hormonal, mechanical or surgical).

  • Patients with difficulties in understanding or using the devices studied.

  • Patients with a contraindication to the use of one of the studied devices.

  • Patients with a history of relevant shoulder surgery

  • Presence of other associated trauma,

  • Previous inclusion in the same study

Exclusion Criteria:
  • Withdrawal of voluntary informed consent from the patient

  • Violation of protocol

  • Presence of a fracture associated with the dislocation (excluding Malgaigne's notches)

  • Posterior, inferior or erecta dislocation

  • Presence of initial vascular and nerve complications

  • Any indication for surgical management

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nice University Hospital Nice France 06000

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nice

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT05821517
Other Study ID Numbers:
  • 21-AOI-11
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2023